Targeting pathway may reduce cocaine’s cardiovascular harms
DALLAS, Feb. 26, 2018 – Scientists have discovered a potential new pathway to treat the harmful effect of cocaine on the cardiovascular system, according to new research in the American Heart Association's journal Hypertension.
Researchers found that excess levels of reactive oxygen species (ROS), molecules known to be found in the aortas of hypertensive animals and humans, are also involved in cocaine-related cardiovascular disease. Reactive oxygen species is a type of unstable molecule that contains oxygen and that easily reacts with other molecules in a cell. A buildup of reactive oxygen species in cells may cause damage to DNA, RNA and proteins and may cause cell death.
The team determined that cocaine activates the molecule microRNA (miR)-30c-5p, increasing ROS levels in the cardiovascular system. But, blocking activation of miR-30c-5p dramatically reduced cocaine-induced cardiovascular impacts.
"The biggest surprise to us was that the modulation of a single miRNA-mRNA pathway could have such a profound effect on cardiovascular function," says Chunming Dong, M.D., study senior author and professor of medicine at University of Miami School of Medicine. "This also suggests that targeting this one pathway may have significant therapeutic benefit, which is an exciting possibility."
In the study, mice injected with cocaine had high blood pressure, stiff blood vessels and excess levels of ROS — all indications of cardiovascular disease. Cocaine exposure also increased levels of the miR-30c-5p molecule in the mice. When the researchers treated the mice to block the increase in miR-30c-5p, the mice did not show high blood pressure, stiffer blood vessels or elevated ROS levels when given cocaine.
This study is the first to identify the role of miR-30c-5p in cocaine-related cardiovascular disease, Dong says. While the results are promising, the study has limitations as it was conducted in mice, Dong notes. The team plans to test the findings to see if they are observed in patients to determine the viability of this targeted pathway.
Co-authors are Wei Zhu, Ph.D.; Huilan Wang, Ph.D.; Jianqin Wei, M.D.; Gregory C. Sartor, Ph.D.; Michelle Meiqi Bao; Clay T. Pierce; Claes R. Wahlestedt, M.D., Ph.D.; and Derek M. Dykxhoorn, Ph.D. Author disclosures are on the manuscript.
A seed grant from the Miami Heart Research Institute supported this study.
- After February 26, view the manuscript and editorial online.
- Follow AHA/ASA news on Twitter @HeartNews
- For the updates and new science from the Hypertension journal follow @HyperAHA
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at http://www.heart.org/corporatefunding.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation's oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1.800.AHA.USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
Related Journal Article